Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Clot-Removal procedure may offer hope for severe brain stem strokes

NCT ID NCT07672795

Disease control Sponsor: The First Affiliated Hospital of University of Science and Technology of China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This trial investigates whether a procedure to remove a blood clot from the basilar artery—a major vessel at the back of the brain—can improve recovery in people with severe stroke. Participants are adults aged 18 to 80 who have a large area of brain damage and can be treated within 24 hours of symptoms. Half receive the clot-removal procedure plus standard medical care, while the other half receive standard care alone. The study measures how many people achieve a good functional outcome after 90 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endovascular therapy (mechanical thrombectomy)
What this could lead to
If successful, this could expand treatment options for severe stroke patients who currently have few alternatives, potentially reducing death and disability.
What could go wrong
This is a mid-stage trial with 256 participants, so results may not apply to all patients. The procedure carries risks like bleeding or vessel damage, and may not improve outcomes over standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 256 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke. * Basilar artery occlusion confirmed by CTA, MRA, or DSA. * Posterior circulation ASPECTS \<7 on CT, CTA source images, or MRI-DWI. * Age 18 to 80 years. * Time from symptom onset or last known well to randomization within 24 hours. * Written informed consent obtained from the patient or legally authorized representative. * Baseline NIHSS score ≥6 before randomization. Exclusion Criteria: * Pre-stroke modified Rankin Scale score ≥3. * Pregnancy or lactation. * Known allergy to contrast agents or nickel-titanium alloy. * Current participation in another clinical trial. * Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg that cannot be controlled with antihypertensive therapy. * Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \>1.7. * Blood glucose \<50 mg/dL or \>400 mg/dL, platelet count \<50 × 10\^9/L, or hematocrit \<25%. * Life expectancy less than 1 year. * Inability to complete 90-day follow-up. * Definite history of cerebral vasculitis. * Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment. * Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \<5 mm on MRI. * Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment. * Intracranial tumor, except for small meningioma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basilar artery occlusion ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke Basilar artery occlusion Large ischemic core

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.